Efficacy on supragingival plaque control of cetylpyridinium chloride in a slow-release dosage form.
To evaluate the relative efficacy of a non-degradable osmotic slow-release dosage form containing 6.6 mg cetylpyridinium chloride (MOTS [Mucosal Oral Therapeutic System] CPC) to inhibit new plaque formation and gingivitis, a single-blind, randomised, parallel group pilot study was set up. 52 healthy volunteers were assigned to receive one of the following treatments for 18 days of non-brushing: holding 1 MOTS CPC 2 x daily for 2 h intra-orally, or rinsing 30 s with 15 ml Peridex 2 x daily, or dissolve Cepacol (each 1.6 mg CPC) lozenges 2 x daily unsupervised. Before the test period, the subjects received a thorough tooth cleaning followed by tooth polishing 1 x a week for 3 weeks to achieve clinical gingival health. After the start of therapy, the subjects were examined at day 4, 7 (+/- 2), 14 (+/- 2) and 18 (2 +/-). Relative efficacy was assessed by the modified Navy plaque index, the Quigley and Hein index, the planimetric plaque index, as well as the papillary marginal gingival index. There was an increase in both plaque formation and gingivitis over the 18 +/- 2 day period of nonbrushing for all subjects in the study. Peridex was the most effective in inhibiting plaque and gingivitis formation over that period of time. There was no difference between MOTS CPC and Cepacol at any time point in plaque accumulation and gingivitis intensity. Peridex was considered more convenient than MOTS CPC. Cepacol resulted in more staining at 18 days than MOTS CPC and Peridex.
Vandekerckhove
B N
BN
Department of Periodontology, Faculty of Medicine, Catholic University of Leuven, Belgium.
Van Steenberghe
D
D
Tricio
J
J
Rosenberg
D
D
Encarnacion
M
M
D000293:Adolescent; D000328:Adult; D000891:Anti-Infective Agents, Local / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D002594:Cetylpyridinium / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D002710:Chlorhexidine / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives / Q000627:therapeutic use; D003692:Delayed-Action Preparations; D003773:Dental Plaque / Q000382:microbiology / Q000517:prevention & control*; D003774:Dental Plaque Index; D003777:Dental Prophylaxis; D004361:Drug Tolerance; D005260:Female; D005891:Gingivitis / Q000517:prevention & control; D006801:Humans; D008297:Male; D009067:Mouthwashes; D010512:Periodontal Index; D010865:Pilot Projects; D016037:Single-Blind Method; D013607:Tablets
D000891:Anti-Infective Agents, Local; D003692:Delayed-Action Preparations; D009067:Mouthwashes; D013607:Tablets; D002594:Cetylpyridinium; C010882:chlorhexidine gluconate; D002710:Chlorhexidine